{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:45:16Z","timestamp":1792111516072,"version":"4.4.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Patients with endogenous Cushing\u2019s syndrome (CS) have increased malignancy risk. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for diabetes and obesity, yet their oncologic outcomes in CS remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the association between GLP-1RA exposure and incident malignancy in patients with CS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a nationwide cohort study using the Clalit Health Services database in Israel, including patients with endogenous CS diagnosed between 2000 and 2023. Patients with adrenal carcinoma or ectopic CS were excluded. Glucagon-like peptide-1 receptor agonist exposure was defined as \u22653 prescription dispensations and modeled as a time-varying variable. The main outcome was incident malignancy following a CS diagnosis in GLP-1RA\u2013exposed vs nonexposed patients. Sensitivity analyses included a 12-month lag-period approach and stratification by remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 609 patients with CS (mean age \u00b1 SD, 48.05 \u00b1 17.17 years; 65.02% women). During a mean follow-up of 14.7 \u00b1 6.4 years, 116 patients developed cancer and 141 died. Overall, 137 patients (22.5%) received GLP-1RA therapy. A total of 8159.69 nonexposed and 795.88 exposed person-years were accrued, with cancer incidence rates of 12.50 and 17.59 per 1000 person-years, respectively. In time-varying competing risk analysis, GLP-1RA exposure was not associated with increased malignancy risk (hazard ratio [HR] 1.65; 95% CI, 0.94-2.90), with consistent results after adjustment (adjusted HR 1.22; 95% CI, 0.45-3.29). Findings were similar in lag-period and remission-stratified analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this nationwide cohort of patients with CS, GLP-1RA exposure was not associated with altered malignancy risk. These findings provide reassuring evidence regarding the oncologic safety of GLP-1RAs in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag223","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:33:37Z","timestamp":1780400017000},"page":"3102-3110","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing\u2019s syndrome"],"prefix":"10.1210","volume":"111","author":[{"given":"Idit","family":"Dotan","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center , Petah Tikva 4941492 ,","place":["Israel"]},{"name":"Gray Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv 69978 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzipora","family":"Shochat","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Rabin Medical Center, Beilinson Hospital , Petah Tikva 4941492 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Kushnir","sequence":"additional","affiliation":[{"name":"Research Authority, Rabin Medical Center, Beilinson Hospital , Petah Tikva 4941492 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Diker-Cohen","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center , Petah Tikva 4941492 ,","place":["Israel"]},{"name":"Gray Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv 69978 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Rudman","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center , Petah Tikva 4941492 ,","place":["Israel"]},{"name":"Gray Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv 69978 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, LMU Hospital, LMU Munich , Munich 80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University , Portland, OR 97239 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-344X","authenticated-orcid":false,"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center , Petah Tikva 4941492 ,","place":["Israel"]},{"name":"Gray Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv 69978 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"10418","key":"2026101520015528000_dgag223-B1","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","article-title":"Cushing's syndrome","volume":"402","author":"Gadelha","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"2026101520015528000_dgag223-B2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"2026101520015528000_dgag223-B3","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/db25-0120","article-title":"Cushing syndrome, hypercortisolism, and glucose homeostasis: a review","volume":"74","author":"De Fronzo","year":"2025","journal-title":"Diabetes"},{"issue":"5","key":"2026101520015528000_dgag223-B4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing's disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2026101520015528000_dgag223-B5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1210\/clinem\/dgaf693","article-title":"Cardiometabolic outcomes after surgical remission of endogenous hypercortisolism: a prospective cohort study","volume":"111","author":"Chacko","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026101520015528000_dgag223-B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"2026101520015528000_dgag223-B7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"issue":"6","key":"2026101520015528000_dgag223-B8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2026101520015528000_dgag223-B9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s43018-025-01110-1","article-title":"Glucagon-like peptide-1 medicines and cancer","volume":"7","author":"Yabut","year":"2026","journal-title":"Nat Cancer"},{"issue":"1","key":"2026101520015528000_dgag223-B10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"},{"issue":"10","key":"2026101520015528000_dgag223-B11","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jnci\/djaf163","article-title":"Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study","volume":"117","author":"Mao","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2026101520015528000_dgag223-B12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101520015528000_dgag223-B13","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24366","article-title":"Association of glucagon-like peptide-1 receptor agonists with cancer risk in older adults with type 2 diabetes","author":"Lu","year":"2025","journal-title":"Obesity"},{"issue":"7","key":"2026101520015528000_dgag223-B14","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2026101520015528000_dgag223-B15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026101520015528000_dgag223-B16","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2026101520015528000_dgag223-B17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists","volume":"179","author":"Ko","year":"2026","journal-title":"Ann Intern Med"},{"issue":"8","key":"2026101520015528000_dgag223-B18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2026101520015528000_dgag223-B19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ejendo\/lvae098","article-title":"Endogenous Cushing's syndrome and cancer risk","volume":"191","author":"Rudman","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026101520015528000_dgag223-B20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ejendo\/lvaf028","article-title":"Impact of remission status in endogenous Cushing's syndrome on cancer incidence","volume":"192","author":"Rudman","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026101520015528000_dgag223-B21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11102-024-01482-0","article-title":"Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis","volume":"28","author":"Rudman","year":"2024","journal-title":"Pituitary"},{"issue":"4","key":"2026101520015528000_dgag223-B22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11102-025-01550-z","article-title":"Weight gain reversibility and BMI following treatment for Cushing's syndrome: long-term outcomes and potential predictors","volume":"28","author":"Sasson","year":"2025","journal-title":"Pituitary"},{"issue":"4","key":"2026101520015528000_dgag223-B23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","article-title":"Mortality in Cushing's syndrome: declining over 2 decades but remaining higher than the general population","volume":"192","author":"Akirov","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026101520015528000_dgag223-B24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Potteg\u00e5rd","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026101520015528000_dgag223-B25","doi-asserted-by":"crossref","unstructured":"Dotan I, Shochat T, Kushnir S, et al \u00a0Supplementary Table 1 for: \u201cGlucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing's syndrome. Figshare. 2026. 10.6084\/m9.figshare.32694555.v1","DOI":"10.1210\/clinem\/dgag223"},{"issue":"10","key":"2026101520015528000_dgag223-B26","doi-asserted-by":"crossref","first-page":"e2540890","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026101520015528000_dgag223-B27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1210\/clinem\/dgag123","article-title":"Mortality risk and causes of death in exogenous Cushing's syndrome: a systematic review and meta-analysis","volume":"111","author":"Limumpornpetch","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026101520015528000_dgag223-B28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12020-026-04587-7","article-title":"Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and\/or obesity in patients with Cushing's syndrome: a multicenter retrospective study","volume":"91","author":"Iglesias","year":"2026","journal-title":"Endocrine"},{"issue":"5","key":"2026101520015528000_dgag223-B29","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/clinem\/dgae405","article-title":"Cushing syndrome is associated with a higher risk of cancer\u2014a nationwide cohort study","volume":"110","author":"Wu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026101520015528000_dgag223-B30","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/en.2017-00461","article-title":"Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kB activation","volume":"158","author":"Iwaya","year":"2017","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag223\/68459736\/dgag223.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3102\/68459736\/dgag223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3102\/68459736\/dgag223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:02:06Z","timestamp":1792108926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/11\/3102\/8700559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag223","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,6,3]]}}}